De progressionsfri overlevelsesrater ved første skemalagte besøg (uge 8) i gruppen med KRAS- vildtypen var 21, 4% for Vectibix plus BSC og 28, 0% for BSC alene, en difference på - 6, 6% (95% CI: - 19, 0; 5, 9).
The progression-free survival rates at the first scheduled visit (week 8) in the KRAS mutant group were 21.4% on Vectibix plus BSC and 28.0% on BSC alone, a difference of -6.6% [95% CI: -19.0, 5.9].